CN110312531A - 治疗性树枝状体 - Google Patents

治疗性树枝状体 Download PDF

Info

Publication number
CN110312531A
CN110312531A CN201880012429.9A CN201880012429A CN110312531A CN 110312531 A CN110312531 A CN 110312531A CN 201880012429 A CN201880012429 A CN 201880012429A CN 110312531 A CN110312531 A CN 110312531A
Authority
CN
China
Prior art keywords
dendrimer
formula
pharmaceutically acceptable
acceptable salt
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880012429.9A
Other languages
English (en)
Chinese (zh)
Inventor
W.麦库尔
M.B.阿什福德
I.格兰特
E.J.亨尼西
J.P.塞克里斯特
D.欧文
B.凯莉
M.吉亚尼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to CN202311534590.1A priority Critical patent/CN117582521A/zh
Publication of CN110312531A publication Critical patent/CN110312531A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Prostheses (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201880012429.9A 2017-02-22 2018-02-22 治疗性树枝状体 Pending CN110312531A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311534590.1A CN117582521A (zh) 2017-02-22 2018-02-22 治疗性树枝状体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762461983P 2017-02-22 2017-02-22
US62/461983 2017-02-22
US201762488151P 2017-04-21 2017-04-21
US62/488151 2017-04-21
US201762591823P 2017-11-29 2017-11-29
US62/591823 2017-11-29
PCT/EP2018/054420 WO2018154004A1 (en) 2017-02-22 2018-02-22 Therapeutic dendrimers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311534590.1A Division CN117582521A (zh) 2017-02-22 2018-02-22 治疗性树枝状体

Publications (1)

Publication Number Publication Date
CN110312531A true CN110312531A (zh) 2019-10-08

Family

ID=61386833

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880012429.9A Pending CN110312531A (zh) 2017-02-22 2018-02-22 治疗性树枝状体
CN202311534590.1A Pending CN117582521A (zh) 2017-02-22 2018-02-22 治疗性树枝状体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311534590.1A Pending CN117582521A (zh) 2017-02-22 2018-02-22 治疗性树枝状体

Country Status (23)

Country Link
US (4) US10314920B2 (cg-RX-API-DMAC7.html)
EP (1) EP3585441A1 (cg-RX-API-DMAC7.html)
JP (1) JP7074761B2 (cg-RX-API-DMAC7.html)
KR (2) KR20230093346A (cg-RX-API-DMAC7.html)
CN (2) CN110312531A (cg-RX-API-DMAC7.html)
AU (1) AU2018223149B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019016409A2 (cg-RX-API-DMAC7.html)
CA (1) CA3053069A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019002240A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019009722A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190361A (cg-RX-API-DMAC7.html)
DO (1) DOP2019000204A (cg-RX-API-DMAC7.html)
EC (1) ECSP19056271A (cg-RX-API-DMAC7.html)
IL (1) IL268648B (cg-RX-API-DMAC7.html)
JO (1) JOP20190191B1 (cg-RX-API-DMAC7.html)
MX (1) MX2019009442A (cg-RX-API-DMAC7.html)
NI (1) NI201900088A (cg-RX-API-DMAC7.html)
PE (1) PE20191660A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501896A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201907334QA (cg-RX-API-DMAC7.html)
TW (1) TWI773730B (cg-RX-API-DMAC7.html)
UA (1) UA125655C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018154004A1 (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112543664A (zh) * 2018-08-17 2021-03-23 阿斯利康(瑞典)有限公司 树枝状体配制品
CN112584869A (zh) * 2018-08-17 2021-03-30 阿斯利康(瑞典)有限公司 用于治疗癌症的方法的缀合物
WO2021213492A1 (zh) * 2020-04-24 2021-10-28 上海森辉医药有限公司 一类载药的大分子及其制备方法
WO2022007940A1 (zh) * 2020-07-10 2022-01-13 江苏恒瑞医药股份有限公司 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用
WO2022042583A1 (zh) 2020-08-25 2022-03-03 上海森辉医药有限公司 载药的大分子及其制备方法
CN115260152A (zh) * 2021-04-30 2022-11-01 江苏恒瑞医药股份有限公司 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180326081A1 (en) * 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
TWI773730B (zh) * 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
CN113056469B (zh) * 2018-11-20 2025-05-23 星法马私人有限公司 治疗性树状聚体
EP3965567B1 (en) 2019-05-07 2023-07-05 Syddansk Universitet Mechanism for dispensing biological material
CN114585389A (zh) * 2019-09-26 2022-06-03 星法马私人有限公司 治疗性树枝状大分子
CA3163886A1 (en) * 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
BR112022012283A2 (pt) 2019-12-20 2022-08-30 Recurium Ip Holdings Llc Combinações
JP2023522984A (ja) 2020-04-24 2023-06-01 アシュバッタ セラピューティクス， インコーポレイテッド 重症急性呼吸促迫症候群の処置のためのデンドリマー組成物および方法
US20230263900A1 (en) * 2020-08-31 2023-08-24 Starpharma Pty Ltd. Dendrimer-drug conjugate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120035134A1 (en) * 2010-08-06 2012-02-09 Astrazeneca Ab Chemical compounds
CN103796684A (zh) * 2011-06-06 2014-05-14 星法马私人有限公司 大分子
WO2015035446A1 (en) * 2013-09-10 2015-03-19 Starpharma Pty Ltd Macromolecules of dendrimer-platinum conjugates
CN104524596A (zh) * 2006-01-20 2015-04-22 星药股份有限公司 经修饰的大分子

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4410688A (en) * 1981-04-29 1983-10-18 Allied Corporation Macromolecular highly branched homogeneous compound
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
HUE031341T2 (hu) * 2005-10-25 2017-07-28 Starpharma Pty Ltd Ellenõrzött sztöchiometriájú makromolekuláris vegyületek
US9127130B2 (en) * 2006-08-11 2015-09-08 Starpharma Pty Ltd. Polylysine dendrimer contrast agent
WO2008017125A1 (en) * 2006-08-11 2008-02-14 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
AU2007319209B2 (en) 2006-11-15 2012-04-19 Genentech, Inc. Arylsulfonamide compounds
US9283302B2 (en) 2011-12-16 2016-03-15 Cormatrix Cardiovascular, Inc. Extracellular matrix encasement structures and methods
WO2009036035A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors
CN102076331B (zh) 2008-06-26 2013-12-18 普罗林科斯有限责任公司 具有可控的药物释放速率的前药和药物-大分子轭合物
US8216549B2 (en) * 2008-07-25 2012-07-10 National Health Research Institutes Method for making a ligand-quantum dot conjugate
NZ614305A (en) 2008-12-05 2015-03-27 Abbvie Inc Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
ES2546294T7 (es) 2009-05-26 2024-06-06 Abbvie Ireland Unlimited Co Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
US20120269721A1 (en) * 2009-10-12 2012-10-25 The Regents Of The University Of California Targeted nanoclusters and methods of their use
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
WO2011140376A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from dendrimers
WO2011140393A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
EP3152248B1 (en) * 2014-06-06 2019-10-09 Starpharma Pty Ltd Dendrimer-drug conjugates
TWI773730B (zh) * 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
TWI856967B (zh) * 2018-08-17 2024-10-01 瑞典商阿斯特捷利康公司 樹枝狀體配製物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104524596A (zh) * 2006-01-20 2015-04-22 星药股份有限公司 经修饰的大分子
US20120035134A1 (en) * 2010-08-06 2012-02-09 Astrazeneca Ab Chemical compounds
WO2012017251A1 (en) * 2010-08-06 2012-02-09 Astrazeneca Ab N-acylsulfonamide apoptosis promoters
CN103796684A (zh) * 2011-06-06 2014-05-14 星法马私人有限公司 大分子
WO2015035446A1 (en) * 2013-09-10 2015-03-19 Starpharma Pty Ltd Macromolecules of dendrimer-platinum conjugates

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARTIN ASSADI等: "《Novel Chlorambucil-conjugated anionic linearglobular PEG-based second-generation dendrimer：in vitro/in vivo improved anticancer activity》", 《ONCO TARGETS AND THERAPY》 *
LISA M.KAMINSKAS等: "Doxorubicin-Conjugated PEGylated Dendrimers Show Similar Tumoricidal Activity but Lower Systemic Toxicity When Compared to PEGylated Liposome and Solution Formulations in Mouse and Rat Tumor Models", 《MOLECULA PHARMACEUTICS》 *
张少飞等: "肽类树枝大分子的合成及其在药物传输系统中的应用", 《化学学报》 *
曾世通等: "多肽树枝状大分子合成的研究进展", 《高分子通报》 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112543664A (zh) * 2018-08-17 2021-03-23 阿斯利康(瑞典)有限公司 树枝状体配制品
CN112584869A (zh) * 2018-08-17 2021-03-30 阿斯利康(瑞典)有限公司 用于治疗癌症的方法的缀合物
WO2021213492A1 (zh) * 2020-04-24 2021-10-28 上海森辉医药有限公司 一类载药的大分子及其制备方法
WO2022007940A1 (zh) * 2020-07-10 2022-01-13 江苏恒瑞医药股份有限公司 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用
CN115697967A (zh) * 2020-07-10 2023-02-03 江苏恒瑞医药股份有限公司 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用
CN115697967B (zh) * 2020-07-10 2024-10-22 江苏恒瑞医药股份有限公司 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用
TWI914377B (zh) 2020-07-10 2026-02-11 大陸商江蘇恆瑞醫藥股份有限公司 磺醯苯甲醯胺類衍生物及其偶聯物、其製備方法及其應用
WO2022042583A1 (zh) 2020-08-25 2022-03-03 上海森辉医药有限公司 载药的大分子及其制备方法
CN115260152A (zh) * 2021-04-30 2022-11-01 江苏恒瑞医药股份有限公司 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用

Also Published As

Publication number Publication date
BR112019016409A2 (pt) 2020-04-07
CL2019002240A1 (es) 2019-11-29
NI201900088A (es) 2020-03-18
US11717574B2 (en) 2023-08-08
SG11201907334QA (en) 2019-09-27
WO2018154004A1 (en) 2018-08-30
JOP20190191A1 (ar) 2019-08-08
MX2019009442A (es) 2019-10-09
US20180264127A1 (en) 2018-09-20
US20200069810A1 (en) 2020-03-05
CO2019009722A2 (es) 2019-09-18
PE20191660A1 (es) 2019-11-11
US20240115716A1 (en) 2024-04-11
CA3053069A1 (en) 2018-08-30
CN117582521A (zh) 2024-02-23
IL268648A (en) 2019-10-31
TW201841659A (zh) 2018-12-01
UA125655C2 (uk) 2022-05-11
WO2018154004A9 (en) 2018-12-27
US10888624B2 (en) 2021-01-12
TWI773730B (zh) 2022-08-11
AU2018223149B2 (en) 2021-04-01
KR20230093346A (ko) 2023-06-27
KR102544033B1 (ko) 2023-06-14
EP3585441A1 (en) 2020-01-01
US20210060172A1 (en) 2021-03-04
CR20190361A (es) 2019-09-24
KR20190112330A (ko) 2019-10-04
US10314920B2 (en) 2019-06-11
PH12019501896A1 (en) 2019-10-21
JP7074761B2 (ja) 2022-05-24
JP2020508985A (ja) 2020-03-26
AU2018223149A1 (en) 2019-10-03
DOP2019000204A (es) 2019-08-30
IL268648B (en) 2022-04-01
ECSP19056271A (es) 2019-08-30
JOP20190191B1 (ar) 2024-04-16

Similar Documents

Publication Publication Date Title
US11717574B2 (en) Therapeutic dendrimers
TWI742074B (zh) Mcl-1抑制劑及其使用方法
JP7506659B2 (ja) 癌を処置する方法に用いられるコンジュゲート
HK40108454A (en) Therapeutic dendrimers
US12115174B2 (en) Dendrimer formulations
HK40013356A (en) Therapeutic dendrimers
EA041072B1 (ru) Терапевтические дендримеры
HK40050834A (en) Conjugates for use in methods of treating cancer
HK40048538A (en) Dendrimer formulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013356

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20191008